Therapy Area | Project - Indication | Non-clinical | Phase I | Phase II | Phase III | Filed |
---|---|---|---|---|---|---|
Reproductive Medicine & Women's Health | FE 999310 Infertility | yes | ||||
FE 202767 Lactation | yes | |||||
BARUSIBAN Implantation Support | yes | |||||
MILPROSA Progesterone vaginal ring Luteal phase support | yes | |||||
Urology | TESTAVAN (testosterone gel) Male hypogonadism | yes | ||||
Gastroenterology | FE 203799 Indication to be determined | yes | ||||
Endocrinology | ||||||
Orthopaedics | AMPLEX (B2A peptide + tricalcium phosphate ceramic granules) Foot & Ankle Fusion | yes | ||||
PREFIX (B2A peptide + tricalcium phosphate ceramic granules) Lumbar Spine Fusion | yes | |||||
CONDOLIASE (chrondroitin-sulfate-ABC endolyase) Radicular leg pain (e.g. sciatica) due to lumbar disc herniation | yes |
FERRING INTERNATIONAL CENTER S.A.
CH. DE LA VERGOGNAUSAZ 50
1162 SAINT-PREX
SWITZERLAND
TEL: +41 58 301 00 00
FAX: +41 58 301 00 10
This global corporate website provides general information about the global Ferring Group. For information about Ferring or its products in a specific country, please select your country in the Global Locator. FERRING, the FERRING PHARMACEUTICALS logo and other Ferring product trade names are trademarks of Ferring B.V. save where indicated otherwise.
©2017 Ferring B.V.